For investors looking for steady income, a methodical way to pick dividend stocks can find companies that provide more than a large payout. A typical plan filters for stocks that join a good, lasting dividend history with sound basic business strength and earnings. This process tries to sidestep the dangers of high-payout stocks that may be unstable—businesses whose distributions could be in danger from money troubles—and instead centers on firms with the monetary strength to keep and possibly raise their dividends over years. One business that appears from this kind of careful filtering is Novartis AG-Sponsored ADR (NYSE:NVS).
A Detailed View of the Dividend History
Novartis makes a strong argument for dividend-oriented investors, mainly seen in its ChartMill Dividend Rating of 7 out of 10. This rating combines a number of important elements needed for judging income-producing stocks.
- Yield and Comparison: The business provides a yearly dividend yield near 2.96%. This is not the biggest yield possible, but it is good in its setting. This yield is notably higher than the norm for the pharmaceuticals field and is also above the present average yield of the S&P 500.
- History and Increase: Consistency is a key part of dividend investing, and Novartis shows a dependable record. The business has given dividends for over ten years and has not cut its payment in the last five years. The dividend has increased at a yearly rate near 5.38% over this time, showing a dedication to giving more capital back to shareholders.
- Payout Lasting Power: Maybe the most important part for long-term income investors is how long the dividend can last. Novartis uses about 56% of its income for dividends. This is a sensible amount that keeps a good part of profits for putting back into the business. Significantly, the business's earnings are rising quicker than its dividend, which hints the present payout level can last and allows for possible future raises.
Supported by Good Earnings and Money Strength
A solid dividend is only as reliable as the business that backs it. The filtering rules that stress "acceptable earnings and strength" are key because they find the source that pays for the dividend. Novartis does well here, with a ChartMill Profitability Rating of 9 and a Health Rating of 7.
- Very Good Earnings: The business's skill to make profits is excellent in its field. Main measures show this:
- Return on Invested Capital (ROIC): At 19.32%, this shows very effective use of capital.
- Profit Margins: An operating margin of 33.18% and a net profit margin close to 25% are with the best in the pharmaceuticals industry.
- Direction: These margins have gotten better in recent years, pointing to better operational effectiveness.
- Firm Money Base: The business's money strength gives trust in its ability to handle economic changes without putting its dividend at risk.
- Stability: Novartis has an Altman-Z score of 4.41, which points to a very small short-term chance of money trouble. Its debt amount, when weighed against its good free cash flow, seems controllable.
- Capital Use: The business has been lowering its share count over recent years, a mark of careful capital use that can help shareholders.
Price and Increase Setting
From a price view, Novartis trades at a P/E ratio near 17, which is lower than most of its industry rivals and the wider S&P 500. When weighing its good earnings, this price seems fair. Increase forecasts are modest, with analysts predicting middle single-digit percentage growth in both earnings and income in the next few years. For a dividend investor, this picture of steady, profitable increase from a field leader can be more attractive than unstable, high-increase speculation, as it backs the regularity of the income flow.
Why the Filtering Rules are Important
This review highlights the reasoning behind the first filtering plan. The high Dividend Rating confirms Novartis as a real income choice. The very good Profitability Rating makes sure the dividend is paid by a successful business, not debt or asset sales. The firm Health Rating gives confidence that the business has the balance sheet strength to keep payments in hard times. Combined, these ratings help sort for businesses where the dividend is a trait of a good business, not a cover for basic problems. A complete look at these basic ratings is in the full ChartMill Fundamental Analysis report for NVS.
Novartis AG, with its dependable dividend history, lasting payout level, and base of very good earnings and money strength, is a clear example of the kind of stock dividend investors might find through a methodical filtering process. It shows a possible mix of income and quality in the healthcare field.
For investors wanting to look at other businesses that fit similar rules of good dividends, earnings, and money strength, the fully set Best Dividend Stocks screen can be a beginning for more study.
Disclaimer: This article is for information only and is not financial advice, a suggestion, or a deal to buy or sell any securities. The review uses present data and past results, which do not show future outcomes. Investors should do their own study and talk with a qualified financial advisor before making any investment choices.